Date: Tuesday 23 April 2019, 10.30am – 11.30am
Title: Impact of stem cell biology and cell trafficking from bench to clinic in skeletal translational research
Speaker: Professor Ming Hao Zheng MD, PhD, FRCPath, FRCPA
Associate Dean (International) and Professor and Director of Research, Translational Orthopaedic Research Centre, The University of Western Australia
Impact of stem cell biology and cell trafficking from bench to clinic in skeletal translational research
Professor Ming-Hao Zheng is the Winthrop Professor and Director of Research at the Translational Orthopaedic Research Centre, Sir Charles Gairdner Hospital, Perth and the Associate Dean (International) of the Faculty of Medicine, Dentistry and Health Sciences, the University of Western Australia. He is also the Chung Kong Scholar Lecturing Professor and the Deputy Director of Australia-China Cooperative Research Centre for Biotherapeutics and Regenerative Medicine at the Zhejiang University, China, Director for UWA-Nanjing Bone and Joint Research Centre at Nanjing University. He has served on the editorial board member for numbers of orthopaedics, stem cell and pathology journals.
He has focused on the development of an academic career in bone and joint research and regenerative medicine. His productivity is evidenced by the quality of publications and patents, and his ability to transform laboratory research into clinical practice. He has published over 140 peer-reviewed papers in journals including Nature Medicine, Annals of Internal Medicine, Journal of Clinical Investigation, Molecular Cellular Biology, Journal of Biological Chemistry, American Journal of Pathology and Journal of Bone and Mineral Research.
His major achievements include studies in the molecular and cellular biology of the osteoclast, clinical and laboratory evaluation of cellular therapies, human bone allograft, development of cell-scaffold technology for cartilage, tendon and bone regeneration and regulatory framework in human tissue and cellular products. His work on Giant Cell Tumour of bone (GCT) has been used by WHO for classification of bone tumours and has been recorded in the textbook “Ackermans Surgical Pathology”.
He has seven patents in the field of orthopaedics and has introduced the concept and technology of autologous biotherapy in orthopaedics. His research results in the development of autologous stem cell and progenitor cell therapy in bone, cartilage and tendon. He has transformed the benchwork of Matrix-induced Autologous Chondrocyte Implantation (MACI) and Autologous Tencoyte Therapy (ATT) into clinical practices. In 2009, he received an honour from by Genzyme in Boston for his leadership, commitment and dedication to the advancement of MACI. To date, more than 120 hospitals across Australia and over 8,000 patients in the world have used MACI for the treatment of cartilage defects.
Prof Zheng has actively supervised and nursed quality postgraduate students and postdoctoral fellows with 24 PhD and 15 Master of Medical Sciences students completing their degree in the last 15 years. Many of them have won awards at the national and international meetings for their research work and become high profile independent researchers.